About OBiO Technology
OBiO Technology is a company based in Shanghai (China) founded in 2013. It operates as a Professional Services and Managed Services. OBiO Technology has raised $87.09 million across 3 funding rounds from investors including 5Y Capital, Loayal Valley Capital and Chenshan Capital. The company has 692 employees as of December 31, 2024. OBiO Technology offers products and services including Gene Therapy Vector Development, Cell and Gene Therapy CDMO, and Regenerative Medicine CDMO. OBiO Technology operates in a competitive market with competitors including Abzena, Patheon, Syngene, Piramal Group and Panacea Biotec, among others.
- Headquarter Shanghai, China
- Employees 692 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Obio Technology (Shanghai) Corp., Ltd. Class A
-
Annual Revenue
$33.11 M (USD)19.24as on Dec 31, 2024
-
Net Profit
-$44.09 M (USD)-151.54as on Dec 31, 2024
-
EBITDA
-$30.95 M (USD)-63.12as on Dec 31, 2024
-
Total Equity Funding
$87.09 M (USD)
in 3 rounds
-
Latest Funding Round
$44.21 M (USD), Series C
Sep 23, 2020
-
Investors
5Y Capital
& 11 more
-
Employee Count
692
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OBiO Technology
OBiO Technology is a publicly listed company on the SSE with ticker symbol 688238 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of OBiO Technology
OBiO Technology offers a comprehensive portfolio of products and services, including Gene Therapy Vector Development, Cell and Gene Therapy CDMO, and Regenerative Medicine CDMO.
Gene therapy vectors are developed for research applications.
CDMO services are provided for gene therapy drugs.
Services for regenerative medicine are offered to clients.
Funding Insights of OBiO Technology
OBiO Technology has successfully raised a total of $87.09M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $44.21 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OBiO Technology
OBiO Technology has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include 5Y Capital, Loayal Valley Capital and Chenshan Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A venture capital firm focused on technology and innovation investments.
|
Locked | Locked | Locked | |
|
Mid-market companies are targeted for investment by Loayal Valley Capital.
|
Locked | Locked | Locked | |
|
Chenshan Capital is focused on data-driven industrial internet investments.
|
Locked | Locked | Locked |
Investor details for OBiO Technology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OBiO Technology
Investment portfolio details for OBiO Technology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OBiO Technology
Detailed financials for OBiO Technology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Obio Technology Comparisons
Peer comparison for OBiO Technology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OBiO Technology
OBiO Technology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abzena, Patheon, Syngene, Piramal Group and Panacea Biotec, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of antibody discovery, cell line development, and bio analytics services
|
|
| Locked | Locked | Locked |
Commercial manufacturing and pharmaceutical development services for biopharmaceutical industry
|
|
| Locked | Locked | Locked |
Provider of contract research and manufacturing services for both small molecules and biologics
|
|
| Locked | Locked | Locked |
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate
|
|
| Locked | Locked | Locked |
Developer of biosimilars, vaccines and natural products
|
|
| Locked | Locked | Locked |
Provides enabling tools and services in the life sciences research and bio-production industries
|
Detailed competitors of OBiO Technology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Obio Technology
Complete news archive for OBiO Technology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OBiO Technology
OBiO Technology was founded in 2013 and raised its 1st funding round 7 years after it was founded.
OBiO Technology is headquartered in Shanghai, China.
OBiO Technology is a funded company, having raised a total of $87.09M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at OBiO Technology is 692.
Annual revenue of OBiO Technology is $33.11M as on Dec 31, 2024.
OBiO Technology (Shanghai) Corp., Ltd. is focused on providing solutions in the field of cell and gene therapy. The company offers CRO services for basic research, including gene therapy vector development and drug target studies. Additionally, CDMO services are provided for the development and production of cell and gene therapy drugs, covering clinical and commercial stages. The company also supports regenerative medicine through cell preparation and storage technologies. Operating primarily in the biotechnology sector, OBiO Technology aims to advance health industries through innovative applications.
OBiO Technology's top competitors include Abzena, Syngene and Grand River Aseptic Manufacturing.
OBiO Technology offers Gene Therapy Vector Development, Cell and Gene Therapy CDMO, and Regenerative Medicine CDMO.
Yes, OBiO Technology is publicly traded on SSE under the ticker symbol 688238.
OBiO Technology has 12 investors. Key investors include 5Y Capital, Loayal Valley Capital, Chenshan Capital, Kunlun Fund, and BioTrack Capital.
The ticker symbol of OBiO Technology is 688238 on SSE.